ADCs, AOCs, ATMPs, cell and gene therapies, and oligonucleotide therapeutics represent distinct but interconnected approaches to precision medicine. Let's take a closer look at their manufacturing needs.
- Developing Your Vapor Phase Hydrogen Peroxide Cycle
- Closing The Gap Between Modeling And GMP Predictive Control
- Exploring Earlier Gene Editing For Children With Dr. Haydar Frangoul, Part 2
- Exploring Earlier Gene Editing For Children With Dr. Haydar Frangoul, Part 1
- Beyond The Plate Count: How To Build A Defensible Environmental Monitoring Trend Review
- Want More Sustainable Biopharma Packaging? Try These Levers
- What Europe's Draft Annex 22 Actually Asks Of Human Oversight Of AI
- Fine-Tuning Bioseparation Column Geometry With 3D-Printed Monoliths
CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Beyond Protein A: Efficient Purification Strategies For Misbehaving mAbs
Next-generation antibody formats require more precise purification strategies. Explore how subdomain-specific VHH ligands can address structural heterogeneity, improve purity, and preserve stability.
-
Study Viral Infection In Resting Humans CD4+ T Cells With Synthetic sgRNAs
Discover how Synthego's proprietary synthetic sgRNA, combined with Lonza’s 4D-Nucleofector®, enabled highly efficient gene editing in resting human CD4+ T cells.
-
Turning Urgency Into Progress And Advancing New Hope In AML
A disrupted AML trial stabilized mid-study, cutting genetic testing turnaround to 1–2 days and keeping enrollment on track for patients who can't wait.
-
What FDA CRLs Reveal About Stability
Download our white paper to learn what issues are driving these CRLs and how to build a stronger stability testing program.
-
Smart Scaling For Cell And Gene Therapies
To meet patient demand, advanced therapy manufacturing processes must be commercial ready. CGT sponsors can mitigate risk and protect viability by partnering with a CDMO that prioritizes scalability.
-
Tailoring Viral Clearance Study Design
Viral‑clearance studies need phase‑appropriate design, strong virus stocks, modality‑specific risk assessment, and alignment with evolving regulations for reliable safety outcomes.
-
USP <665> Becomes Official On May 1, 2026. Are You Ready?
With USP <665> becoming official on May 1, 2026, proactive preparation is essential to ensure compliance and prevent delays, regulatory observations, or supply chain disruptions.
-
Innovation In Filtration
Filtration removes contaminants to ensure safety and is essential in various applications, from lab-scale tasks to GMP production. Explore how its simplicity and reliability make it indispensable.
-
A Novel Patient-Derived Colorectal Cancer Organoid Platform
Patient-derived organoids are revolutionizing drug discovery by mimicking tumors and predicting therapeutic efficacy. Discover a scalable bioprocess that enhances reproducibility and cost-effectiveness to pave the way for broader adoption.
-
ddPCR Workflows For Gene Expression Analysis
RT-ddPCR offers a powerful, flexible approach to precise RNA quantification. Learn how one-step and two-step workflows improve sensitivity and efficiency in your gene expression studies.
NEWSLETTER ARCHIVE
- 11.13.26 -- Closing The CAR-T Access Gap With Hospital-Based Manufacturing
- 11.12.26 -- A New Model For Bringing CAR-T To More Patients
- 11.12.26 -- Simplify The Journey Of Advancing Your Therapies To Patients
- 11.12.26 -- The Latest CDMO Opportunities And Threats Report
- 11.11.26 -- Exploring Earlier Gene Editing For Children With Dr. Haydar Frangoul
- What Will It Take To Turn CGT Innovation Into Market Success?
- Exploring Earlier Gene Editing For Children With Dr. Haydar Frangoul, Part 2
- Exploring Earlier Gene Editing For Children With Dr. Haydar Frangoul, Part 1
- Earlier Decisions, Better Processes Required For Automating Autologous CAR T Manufacturing
- Why In Vivo Innovation, Regulatory Convergence Will Help Shape CGT's Next Chapter
EDITORIAL COLLECTIONS KNOWLEDGE CENTER
Our Editorial Collections examine today’s biggest scientific, operational, and patient-centered drug delivery issues. These collections help companies navigate complex development decisions with in-depth analysis, real-world examples, and guidance from industry experts
More Editorial Collections

